Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

The biology of VEGF and its receptors

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · see citing works

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works

Vascular Endothelial Growth Factor: Basic Science and Clinical Progress

Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,707 · see citing works

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works

‘Green mice’ as a source of ubiquitous green cells

Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T., & Nishimune, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00313-x · Cited by 2,581 · see citing works

TGF-β Signaling in Tumor Suppression and Cancer Progression

Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275 · see citing works

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works

Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860 · see citing works

VEGF-Trap: A VEGF blocker with potent antitumor effects

Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · see citing works

Molecular mechanisms of drug resistance

Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,686 · see citing works

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · see citing works

CX 3 CR1-Mediated Dendritic Cell Access to the Intestinal Lumen and Bacterial Clearance

Niess, J. H., Brand, S., Gu, X., Landsman, L., Jung, S., McCormick, B. A., Vyas, J. M., Boes, M. L., Ploegh, H. L., Fox, J. G., et al. (2005) · Science · doi:10.1126/science.1102901 · Cited by 1,609 · see citing works

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1

Barleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marmé, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,350 · see citing works

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · see citing works

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Good, D. J., Polverini, P. J., Rastinejad, F., Beau, M. M. L., Lemons, R. S., Frazier, W. A., & Bouck, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6624 · Cited by 1,051 · see citing works

Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation.

Edfeldt, K., Swedenborg, J., Hansson, G. K., & Yan, Z.-Q. (2002) · PubMed · Cited by 847 · see citing works

The Biology of Hematopoietic Stem Cells

Morrison, S. J., Uchida, N., & Weissman, I. L. (1995) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cb.11.110195.000343 · Cited by 774 · see citing works

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

Gerber, H., Malik, A. K., Solar, G. P., Sherman, D. A., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002) · Nature · doi:10.1038/nature00821 · Cited by 706 · see citing works

Expression of Toll-Like Receptors in Human Atherosclerotic Lesions

Edfeldt, K., Swedenborg, J., Hansson, G. K., & Yan, Z.-Q. (2002) · Circulation · doi:10.1161/circ.105.10.1158 · Cited by 706 · see citing works

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

Hattori, K., Heissig, B., Wu, Y. L., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Böhlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 632 · see citing works

Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies

Gerber, H., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626 · see citing works

Vascular endothelial growth factor is essential for corpus luteum angiogenesis

Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H. P., Nguyen, T.-N., Peers, D. H., Chisholm, V., Hillan, K. J., & SCHWALL, R. H. (1998) · Nature Medicine · doi:10.1038/nm0398-336 · Cited by 624 · see citing works

Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells

Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527 · see citing works

Blocking IL-1 in systemic inflammation

Dinarello, C. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050640 · Cited by 494 · see citing works

Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities

Hida, K., Hida, Y., Amin, D. N., Flint, A., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470 · see citing works

Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells

Hestdal, K., Ruscetti, F. W., Ihle, J. N., Jacobsen, S. E. W., Dubois, C. M., Kopp, W. C., Longo, D., & Keller, J. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.1.22 · Cited by 464 · see citing works

Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF

Liang, W., Wu, X., Peale, F. V., Jr., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H., Ferrara, N., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 345 · see citing works

Immature myeloid cells and cancer-associated immune suppression

Kusmartsev, S. A., & Gabrilovich, D. I. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297 · see citing works

VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis

Dong, J., Grunstein, J., Tejada, M. L., Peale, F., Frantz, G. D., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 294 · see citing works

CD83 on dendritic cells: more than just a marker for maturation

Lechmann, M., Berchtold, S., Steinkasserer, A., & Hauber, J. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02214-7 · Cited by 251 · see citing works

Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Gerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 249 · see citing works

Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches

Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria‐Petit, A., Klement, G. L., Coomber, B. L., & Rak, J. W. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 236 · see citing works

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials

Maïo, M. D., Gridelli, C., Gallo, C., Shepherd, F. A., Piantedosi, F. V., Cigolari, S., Manzione, L., Illiano, A., Barbera, S., Robbiati, S. F., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70255-2 · Cited by 235 · see citing works

The role of MIP-1α in Inflammation and hematopoiesis

Cook, D. N. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.59.1.61 · Cited by 217 · see citing works

The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade.

Davis-Smyth, T., Chen, H., Park, J., Presta, L. G., & Ferrara, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00872.x · Cited by 199 · see citing works

Tumor Inflammatory Angiogenesis and Its Chemoprevention

Albini, A., Tosetti, F., Benelli, R., & Noonan, D. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3473 · Cited by 192 · see citing works

Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung

Favre, C. J., Mancuso, M. R., Maas, K., et al. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00983.2002 · Cited by 147 · see citing works

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): Receptor biology, signal transduction, and neutrophil activation

Rapoport, A. P., Abboud, C. N., & DiPersio, J. F. (1992) · Blood Reviews · doi:10.1016/0268-960x(92)90007-d · Cited by 135 · see citing works

IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain.

Palmer-Crocker, R., Hughes, C. C. W., & Pober, J. S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118829 · Cited by 112 · see citing works

IL‐13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats

Roy, B., Bhattacharjee, A., Xu, B., Ford, D., Maizel, A. L., & Cathcart, M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.3.580 · Cited by 105 · see citing works

Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow–hematopoietic progenitor cells expressing SDF-1–intrakine

Onai, N., Zhang, Y., Yoneyama, H., Kitamura, T., Ishikawa, S., & Matsushima, K. (2000) · Blood · doi:10.1182/blood.v96.6.2074 · Cited by 104 · see citing works

Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice

Feau, S., Facchinetti, V., Granucci, F., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1059 · Cited by 95 · see citing works

Nerve Growth Factor (NGF) Promotes Angiogenesis in the Quail Chorioallantoic Membrane

Lazarovici, P., Gazit, A., Staniszewska, I., Marcinkiewicz, C., & Lelkes, P. I. (2006) · Endothelium · doi:10.1080/10623320600669053 · Cited by 62 · see citing works

Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C 57 Bl 6 mice with syngeneic melanoma B16

Wald, M., Olejár, T., aacute, V. X. E., et al. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800170004 · Cited by 60 · see citing works

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

Liu, Y., Zhang, W., Chan, T., et al. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00002-4 · Cited by 55 · see citing works

Identification of alterations in DNA copy number in host stromal cells during tumor progression

Pelham, R. J., Rodgers, L., Hall, I. M., Lucito, R., Nguyen, K. C. Q., Navin, N. E., Hicks, J. B., Mu, D., Powers, S., Wigler, M. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609635104 · Cited by 52 · see citing works

Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice

Malik, A. K., Baldwin, M. E., Peale, F. V., Jr., Fuh, G., Liang, W., Lowman, H. B., Meng, G., Ferrara, N., & Gerber, H. (2005) · Blood · doi:10.1182/blood-2005-05-2047 · Cited by 45 · see citing works

Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.

Lemoli, R. M., Gulati, S. C., Strife, A., et al. (1991) · PubMed · Cited by 36 · see citing works

Secretion of Monocyte Chemoattractant Protein-1 (MCP-1) by Human Mononuclear Phagocytes

Leonard, E. J., Skeel, A., Yoshimura, T., & Rankin, J. A. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2952-1_7 · Cited by 25 · see citing works

Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.

Ho, R. L., Maccubbin, D., Ujházy, P., et al. (1993) · PubMed · Cited by 20 · see citing works

Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma

Bobek, V., Kološtová, K., Pinterov, D., et al. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-8118-8 · Cited by 14 · see citing works

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · see citing works

Microenvironmental regulation of metastasis

Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · see citing works

Modes of resistance to anti-angiogenic therapy

Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · see citing works

VEGF in signaling and disease: beyond discovery and development

Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721 · see citing works

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694 · see citing works

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · see citing works

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027 · see citing works

Neutrophils in cancer: Neutral no more

Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830 · see citing works

Tumor microenvironment and therapeutic response

Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802 · see citing works

Macrophage Polarization States in the Tumor Microenvironment

Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631 · see citing works

The role of myeloid cells in the promotion of tumour angiogenesis

Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · see citing works

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · see citing works

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · see citing works

History of myeloid-derived suppressor cells

Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · see citing works

A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis

Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · see citing works

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918 · see citing works

How the ageing microenvironment influences tumour progression

Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849 · see citing works

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · see citing works

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · see citing works

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663 · see citing works

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639 · see citing works

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors

Butler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578 · see citing works

Biomarkers of response and resistance to antiangiogenic therapy

Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572 · see citing works

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · see citing works

The pre-metastatic niche: finding common ground

Sceneay, J., Smyth, M. J., & Möller, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9420-1 · Cited by 422 · see citing works

Anti-angiogenic therapy: current challenges and future perspectives

Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416 · see citing works

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286 · see citing works

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy

Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291 · see citing works

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258 · see citing works

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257 · see citing works

Anti-VEGF therapies in the clinic

Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237 · see citing works

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164 · see citing works

Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?

Yang, L., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2556 · Cited by 151 · see citing works

Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth

Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140 · see citing works

Targeting CXCR4-dependent immunosuppressive Ly6C ^low monocytes improves antiangiogenic therapy in colorectal cancer

Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138 · see citing works

A novel role for platelet secretion in angiogenesis, mediating bone marrow-derived cell mobilization and homing

Feng, W., Madajka, M., Kerr, B. A., Mahabeleshwar, G. H., Whiteheart, S. W., & Byzova, T. V. (2011) · Blood · doi:10.1182/blood-2010-08-304808 · Cited by 133 · see citing works

Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption

Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.010 · Cited by 131 · see citing works

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123 · see citing works

Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression

Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0647 · Cited by 97 · see citing works

Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics

Navarro, P., Bueno, M. J., Zagorac, I., Mondejar, T., Sanchez, J., Mourón, S., Muñoz, J., Gómez-López, G., Jimenez-Renard, V., Mulero, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.052 · Cited by 102 · see citing works

The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade

Nisancioglu, M. H., Betsholtz, C., & Genové, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4245 · Cited by 87 · see citing works

Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis

Singhal, M., Gengenbacher, N., Abdul Pari, A. A., Kamiyama, M., Hai, L., Kuhn, B. J., Kallenberg, D. M., Kulkarni, S. R., Camilli, C., Preuß, S. F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6805 · Cited by 80 · see citing works

A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma

Gyanchandani, R., Ortega Alves, M. V., Myers, J. N., & Kim, S. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0358 · Cited by 73 · see citing works

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43 · see citing works

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Venugopalan, A., Lee, M.-J., Niu, G., Medina-Echeverz, J., Tomita, Y., Lizak, M. J., Cultraro, C. M., Simpson, R. M., Chen, X., Trepel, J. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11021 · Cited by 40 · see citing works

Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of <scp>ER</scp>‐positive breast cancer

von der Lippe Gythfeldt, H., Lien, T., Tekpli, X., Silwal‐Pandit, L., Borgen, E., Garred, Ø., Skjerven, H., Schlichting, E., Lundgren, S., Wist, E., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33108 · Cited by 20 · see citing works

Soluble Triggering Receptor Expressed on Myeloid Cells-1

Lemarie, J., & Gibot, S. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2019.08.004 · Cited by 30 · see citing works

Περιεγχειρητική διακύμανση του αυξητικού παράγοντα αγγειακού ενδοθηλίου (vascular endothelial growth factor/VEGF) σε ασθενείς με καρκίνο παχέος εντέρου και ασθενείς με καρκίνο μαστού

Μπιτσάκου, Γ. (2013) · doi:10.12681/eadd/41000

Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma

Wilkie, M. D., Santosh, S., Emmett, M. S., et al. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2012.06.015

CD200 and membrane protein interactions in the control of myeloid cells

Barclay, A. N., Wright, G. J., Brooke, G. P., & Brown, M. H. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02223-8 · Cited by 416 · see citing works

Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings

Shenavandeh, S., Tarakemeh, T., Sarvestani, E. K., & Nazarinia, M. A. (2016) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2016.03.004 · Cited by 19 · see citing works